Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease

The recruitment status of this study is unknown because the information has not been verified recently.

Verified February 2007 by Shaheed Beheshti Medical University.
Recruitment status was Recruiting

Sponsor:

Information provided by:

Shaheed Beheshti Medical University

ClinicalTrials.gov Identifier:

NCT00370734

First received: August 31, 2006

Last updated: February 26, 2007

Last verified: February 2007

History of Changes

Tracking Information

First Received Date ^ICMJE

August 31, 2006

Last Updated Date

February 26, 2007

Start Date ^ICMJE

May 2005

Primary Completion Date

Not Provided

Current Primary Outcome Measures ^ICMJE

Not Provided

Original Primary Outcome Measures ^ICMJE

Not Provided

Change History

Complete list of historical versions of study NCT00370734 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Not Provided

Original Secondary Outcome Measures ^ICMJE

Not Provided

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Effect of Percutaneous Botulinum Toxin A Injection on Natural Course of Upper Lid Retraction in Thyroid Eye Disease

Official Title ^ICMJE

Not Provided

Brief Summary

In active phase of thyroid eye disease some patients have obvious upper lid retraction , and sometimes exposure keratopathy .To date there is not any standard treatment for this situation . We are going to compare the natural course of the upper lid retraction with injection of botulinum toxin A injection to upper lid percutaneously.

Detailed Description

Not Provided

Study Type ^ICMJE

Interventional

Study Phase

Phase 2
Phase 3

Study Design ^ICMJE

Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Condition ^ICMJE

Eye Diseases

Intervention ^ICMJE

Drug: Botulinum toxin A injection

Study Arm (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Recruiting

Enrollment ^ICMJE

Completion Date

February 2007

Primary Completion Date

Not Provided

Eligibility Criteria ^ICMJE

Inclusion Criteria:

all the patients wiht oper lid retraction in active phase of thyroid ophthalmopathy

Exclusion Criteria:

patients in non active phase

Gender

Both

Ages

Not Provided

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact: Babak Babsharif, MD

+98 21 22585952

labbafi@hotmail.com

Location Countries ^ICMJE

Iran, Islamic Republic of

Administrative Information

NCT Number ^ICMJE

NCT00370734

Other Study ID Numbers ^ICMJE

8375

Has Data Monitoring Committee

Yes

Responsible Party

Not Provided

Study Sponsor ^ICMJE

Shaheed Beheshti Medical University

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Principal Investigator:

Babak Babsharif, MD

Ophthalmic Research Center of Shaheed Beheshti Medical University

Information Provided By

Shaheed Beheshti Medical University

Verification Date

February 2007

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top